Skip to main content
IDWeek 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Session: New Antimicrobials in the Pipeline Part 2

2012 - Helicase-primase inhibitor pritelivir for the treatment of resistant HSV infections in immunocompromised patients

Saturday, October 14, 2023
8:12 AM – 8:24 AM US ET
Location: 104 ABC
Disclosure(s):
Alexander Birkmann, PhD: AiCuris Anti-Infective Cures AG: I am an employee of AiCuris, the company that develops pritelivir, and contributed to patents through AiCuris. (Ongoing)